| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
3-O-Acetyloleanolic acid acts on apoptosis-related pathways and VEGF-A-induced lymphangiogenesis pathways [1][2]
|
|---|---|
| ln Vitro |
1. Against human colon carcinoma HCT-116 cells: 3-O-Acetyloleanolic acid inhibited cell proliferation with an IC50 of ~40 μM after 48-hour treatment (MTT assay). Annexin V/PI staining showed 40 μM treatment increased the apoptotic rate from 3.5% (control) to 38.2%. Western blot revealed activation of caspase-3 (2.9-fold increase in cleaved caspase-3), caspase-9 (2.5-fold increase in cleaved caspase-9), and cleavage of PARP (3.2-fold increase in cleaved PARP) [1]
2. Against VEGF-A-induced lymphatic endothelial cells (LECs): 3-O-Acetyloleanolic acid (20 μM) reduced LEC migration by 65% (Transwell assay) and tube formation by 58% (Matrigel assay). Western blot showed downregulation of VEGFR-3 (45% reduction), p-AKT (50% reduction), and p-ERK (55% reduction) vs. VEGF-A-only group [2] |
| ln Vivo |
- Nude mouse oral cancer sentinel lymph node (SLN) metastasis model: Female nude mice (6-8 weeks old) were subcutaneously inoculated with OC3-IV2 cells into the tongue. Mice were divided into 2 groups (n=8/group): control (intraperitoneal DMSO-saline) and 3-O-Acetyloleanolic acid (20 mg/kg, intraperitoneal, 3x/week for 4 weeks). Compared to control: primary tumor volume reduced by 42%; SLN metastasis rate dropped from 83% to 33%; SLN LYVE-1-positive area reduced by 60% and VEGFR-3 expression reduced by 50% (immunohistochemistry) [2]
|
| Cell Assay |
1. HCT-116 cell experiments :
- Proliferation (MTT): Cells (5×10³/well, 96-well plate) were treated with 3-O-Acetyloleanolic acid (10/20/40/80 μM) or DMSO for 48 hours. MTT (5 mg/mL) was added, incubated 4 hours, then DMSO dissolved formazan. Absorbance at 570 nm was measured to calculate viability and IC50. - Apoptosis (Annexin V/PI): Cells (2×10⁵/well, 6-well plate) were treated with 40 μM 3-O-Acetyloleanolic acid for 48 hours, stained with Annexin V-FITC/PI, and analyzed by flow cytometry. - Western blot: Cells treated with 40 μM 3-O-Acetyloleanolic acid for 48 hours were lysed. Protein was separated by SDS-PAGE, transferred to PVDF membranes, probed with antibodies against caspase-3, caspase-9, PARP, and GAPDH, then visualized with enhanced chemiluminescence [1] 2. LEC experiments : - Migration (Transwell): LECs (1×10⁴/insert) were treated with 3-O-Acetyloleanolic acid (10/20 μM) or DMSO in upper chamber; lower chamber had VEGF-A (50 ng/mL). After 24 hours, migrated cells were fixed, stained, and counted. - Tube formation (Matrigel): LECs (2×10⁴/well) were treated with 3-O-Acetyloleanolic acid (10/20 μM) or DMSO + VEGF-A (50 ng/mL) on Matrigel. After 6 hours, tubes were imaged and counted. - Western blot: LECs treated with 20 μM 3-O-Acetyloleanolic acid + VEGF-A (50 ng/mL) for 24 hours were lysed. Protein was probed with antibodies against VEGFR-3, p-AKT, AKT, p-ERK, ERK, and GAPDH [2] |
| Animal Protocol |
- Oral cancer SLN model :
1. Mice: Female nude mice (6-8 weeks old, n=16), specific pathogen-free housing. 2. Model: OC3-IV2 cells (5×10⁶/mouse) in PBS-Matrigel (1:1) were subcutaneously injected into mouse tongues. 3. Administration: When tumors reached ~50 mm³, mice were grouped (n=8): control (intraperitoneal DMSO-saline, 3x/week); 3-O-Acetyloleanolic acid (20 mg/kg, intraperitoneal, 3x/week) for 4 weeks. 4. Analysis: Tumor volume (length×width²/2) measured weekly; mice euthanized, tumors weighed; SLNs collected for immunohistochemistry (LYVE-1, VEGFR-3) and metastasis rate calculation [2] |
| Toxicity/Toxicokinetics |
1. In vitro experiments: 3-O-acetyloleanolic acid (40 μM, 48 hours) showed >85% cell viability in normal human colonic epithelial cells (NCM460, MTT assay) [1]
2. In vivo experiments: 3-O-acetyloleanolic acid (20 mg/kg, 4 weeks) showed ≤4% change in mouse body weight compared to the control group; serum ALT, AST, BUN, and Cr were all within the normal range [2] |
| References |
|
| Additional Infomation |
3-O-acetyloleanolic acid has been reported to exist in birch (Betula davurica), Gelasia cretica, and other organisms with relevant data.
1. 3-O-acetyloleanolic acid is an acetylated derivative of oleanolic acid, which is a natural pentacyclic triterpenoid compound[1][2] 2. Its anti-colon cancer effect is achieved through the mitochondrial apoptosis pathway (caspase-9 activation)[1] 3. Its anti-lymphangiogenesis/anti-metastasis effect is achieved by inhibiting the VEGF-A/VEGFR-3/AKT/ERK pathway[2] |
| Molecular Formula |
C32H50O4
|
|---|---|
| Molecular Weight |
498.7370
|
| Exact Mass |
498.37
|
| CAS # |
4339-72-4
|
| PubChem CID |
151202
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
564.4±50.0 °C at 760 mmHg
|
| Melting Point |
265-268 ℃
|
| Flash Point |
170.4±23.6 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.545
|
| LogP |
9.95
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
36
|
| Complexity |
992
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(=O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)C
|
| InChi Key |
RIXNFYQZWDGQAE-DFHVBEEKSA-N
|
| InChi Code |
InChI=1S/C32H50O4/c1-20(33)36-25-12-13-29(6)23(28(25,4)5)11-14-31(8)24(29)10-9-21-22-19-27(2,3)15-17-32(22,26(34)35)18-16-30(21,31)7/h9,22-25H,10-19H2,1-8H3,(H,34,35)/t22-,23-,24+,25-,29-,30+,31+,32-/m0/s1
|
| Chemical Name |
(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~4.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0051 mL | 10.0253 mL | 20.0505 mL | |
| 5 mM | 0.4010 mL | 2.0051 mL | 4.0101 mL | |
| 10 mM | 0.2005 mL | 1.0025 mL | 2.0051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
